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Fig 1. Psoriasis vulgaris. Erythematosquamous lesions on
both lower extremities.
Fig 2. Psoriasis vulgaris. Regression of psoriatic lesions
after therapy.
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e60 Lettersdiagnosis can be made with biopsy of mucocuta-
neous lesions, polymerase chain reaction, or direct
antigen assay. Serum serologies and radiographic
findings are typically noncontributory.5
Prompt diagnosis and treatment of HSV reactiva-
tion is paramount because disseminated HSV can
lead to rapid multisystem organ failure and death.
HSV prophylaxis might be considered for patients
starting ruxolitinib therapy, especially in those with a
history of infection with human immunodeficiency
virus. This case underscores the possibility of this
devastating complication from use of this drug.
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Management of psoriasis vulgaris and multiple
sclerosis with fumaric acid
To the Editor: Psoriasis vulgaris has not only been
associated with several comorbidities like metabolic
syndrome and cardiovascular disease, but also with
neurologic disorders like multiple sclerosis (MS).1
New-onset psoriatic lesions and exacerbations have
been described after treatment with biologics for
MS, mainly interferon-beta (INF-) as well as with
other biologics such as natalizumab.2 INF- is the
first-line treatment for clinically isolated syndrome
Open access under CC BY-NC-ND license.with the high risk for MS development or for
relapsing-remitting multiple sclerosis (RR-MS).
Fumaric acids have been a well-established therapy
for psoriasis vulgaris, mainly in Germany under the
trade name Fumadermea mixture of dimethyl
fumarate (DMF) and 3 salts of ethyl hydrogen
fumarate, with DMF considered to be the active
ingredient. In recent years, DMF BG-12 was also
investigated for the treatment of MS. The results of
phase 2 and 3 trials showed successfully reduced
relapse rates and time of disability progression in
patients with MS.3,4
We report a case of a 26-year-old woman in
whom optic neuritis developed. Cerebrospinal
fluid contained 9 oligoclonal bands and multifocal
hemispheral inflammatory lesions typical of MS
were seen on magnetic resonance imagining
(MRI) of the brain. The diagnosis was clinically
isolated syndrome with a high risk for MS devel-
opment. She was initially treated with systemic
corticosteroids and 2 months later INF- treatment
was started. Within half a year, an inflammatory
reaction appeared at the site of injection, which
developed into psoriasiform plaque with gradual
progression to generalized psoriatic lesions (Fig 1).
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INF-, therapy was discontinued; however, the skin
lesions did not resolve. PASI score was 21, BSA was
18%, and PGA was 3. There was no improvement
with UVB phototherapy. Finally, treatment with
fumaric acids was chosen. Fumaric acids are an
approved therapeutic option for psoriasis and are
under investigation for use in cases of MS.
Treatment was started with the recommended
dose for psoriasis, that is, 30 mg/day and gradually
increased to 480 mg/day. Within 6 weeks, PASI
score was improved by 75% (Fig 2). Expected
adverse events such as nausea, diarrhea, and hot
flushes were seen, although the dosing regimen
remained unaltered. After more than 18 months on
treatment with fumarates, the patient’s psoriatic
lesions are stable and no new neurologic symp-
toms have developed. MRI of the brain showed no
further disease progression.
MS is an inflammatory demyelinating disorder
thought to be triggered by autoreactive T cells.
Like psoriasis, it is thought to be a Th1 cell
disease.5 Although it is a very effective therapy
for psoriasis, treatment with biologic agents of the
anti-tumor necrosis factor- group could evoke or
exacerbate preexisting MS. This makes the com-
bination of psoriasis and multiple sclerosis to be a
very challenging situation with respect to man-
agement.6 In the past few years, the oral agent
DMF BG-12 has been investigated for the treat-
ment of MS. In our case, fumaric acids were
efficacious and well tolerated in both psoriasis
and clinically isolated syndrome with a high risk
for MS development. No progression of multiple
sclerosis was observed, which allows us to
consider the use of a single treatment option in
the future for patients simultaneously affected by
both diseases.
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To the Editor: Cold agglutinin disease (CAD) is an
uncommon form of autoimmune hemolytic anemia
that results from complement fixation to IgM agglu-
tinated red blood cells (RBCs).1 These IgM anti-
bodies are known as cold agglutinins (CAs) because
they react at cold temperatures with RBC surface
antigens.2,3 Although hemagglutination has been
reported during cardiopulmonary bypass, there are
no reports of this complication with extracorporeal
photopheresis (ECP).4,5 We present a case of hem-
agglutination that occurred in a patient with CAD
receiving ECP.
The patient was a 73-year-old white man with
Sezary syndrome (SS) undergoing treatment with
bexarotene and ECP. His medical history was signif-
icant for chronic lymphocytic leukemia (CLL) and
chronic macrocytic anemia, which was attributed to
the former. Work-up of the anemia included normal
B12 and folate results and normal colonoscopy.
Following a severe outbreak of herpes zoster, the
patient was receiving his 25th treatment of ECPwhen
agglutinated blood was noted in the centrifuge bowl,
acrylic plates, and tubing. A hemoglobin level
obtained at that time was 7.1 g/dL. A direct
Coombs test was positive for anti-C3d and negative
for anti-IgG, confirming the diagnosis of cold
